Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open
Johnson & Johnson shares closed at $199.96 on December 9, down 0.8% after touching $205.54 intraday. After the bell, the company reported Phase 3 data showing its TECVAYLI® + DARZALEX FASPRO® combination cut multiple myeloma progression or death risk by 83%. JNJ paid a $1.30 quarterly dividend, marking 63 years of dividend growth. Analyst consensus sees modest upside, with targets near $203–207.